Document is current
Any future updates will be listed below
-
Authors
Elliott, Isabel G. https://orcid.org/0000-0003-4535-5932
Fisher, Hayden https://orcid.org/0000-0003-0093-0921
Chan, H. T. Claude
Inzhelevskaya, Tatyana
Mockridge, C. Ian
Penfold, Christine A.
Duriez, Patrick J.
Orr, Christian M. https://orcid.org/0000-0002-6137-8969
Herniman, Julie https://orcid.org/0000-0003-4834-1093
Müller, Kri T. J. https://orcid.org/0000-0001-5674-6125
Essex, Jonathan W. https://orcid.org/0000-0003-2639-2746
Cragg, Mark S.
Tews, Ivo https://orcid.org/0000-0002-4704-1139
-
Funding
Funding for this research was provided by:
Cancer Research UK (DRCPGM\100039, DRCDDRPGM- Apr2020\100005, C1477/A20537, C34999/A18087, C328/A25139)
RCUK | Biotechnology and Biological Sciences Research Council (BB/Y009339/1)
RCUK | Engineering and Physical Sciences Research Council (EP/R029407/1, EP/X035603/1)
- License Information
-
More Information
Article History
Received: 23 July 2024
Accepted: 28 March 2025
First Online: 12 April 2025
Competing interests
: M.S.C. acts as a retained consultant for BioInvent International, consults for several other biotech companies, and receives institutional payments and royalties from antibody licenses. He has received research funding from BioInvent, GSK, iTeos, UCB, Surrozen and Roche. This work is related to patent Family WO 2015/145360 protecting antibodies containing modified hIgG2 domains which elicit agonist or antagonistic properties. JWE receives funding from: G.S.K., A.Z., Astex, UCB, dstl, Diamond Light Source, and exScientia. All other authors declare that they have no competing interests.
